History of a previous renal transplant as the most important event for C3d positive HLA antibodies and IgG subclass identification


Abstract:

Introduction: Antibodies against HLA antigens are the main immunologic barrier for kidney transplantation. These antibodies either preformed, or developed de novo after transplant, precede antibody-mediated rejection, which is the most important cause of graft failure. The capability to further analyze these antibodies is allowing the creation of immunologic risk profiles that are associated with higher rejection rates and graft loss. Some of the most studied risk characteristics of the antibodies are the Mean Fluorescence Intensity (MFI), HLA antigenic specificity, IgG subclasses and the antibodies’ ability to fix complement. The objective of this study is to describe the characteristics of pre-transplant HLA antibodies and the sensitizing events related to them (previous kidney transplant, pregnancies and transfusions). Material and methods: This is an observational, transversal and descriptive study. Sera samples from previously sensitized potential kidney transplant recipients were evaluated; anti-HLA antibodies were determined using single antigen beads (SAB)(Luminex), as well as IgG subclasses of these antibodies and its ability for complement activation using the C3d assay. Results: A total of 89 patients’ sera samples were analyzed, with a mean age 33.3 years (±13.8) and 60.2% males (n= 54). History of previous kidney transplant was found in 20.4%(n= 18) of the patients, history of at least one previous pregnancy 17.2%(n= 15) of the female patients and previous transfusions in 60.2%(n= 54). A total of 1,771 anti-HLA antibodies were detected, 367 (20.1%) with at least one IgG subclass and 216 (12.1%) complement activation capacity (C3d …

Año de publicación:

2020

Keywords:

    Fuente:

    googlegoogle

    Tipo de documento:

    Other

    Estado:

    Acceso abierto

    Áreas de conocimiento:

    • Medicina interna

    Áreas temáticas:

    • Medicina y salud
    • Enfermedades
    • Farmacología y terapéutica

    Contribuidores: